Research programme: FF2 - Nuada
Alternative Names: FF2 research programme - Nuada; Muscarinic M3 receptor antagonists research programme - Nuada; Research programme: muscarinic M3 receptor antagonists - NuadaLatest Information Update: 08 Feb 2008
At a glance
- Originator Nuada Pharmaceuticals
- Class
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Urinary incontinence
Most Recent Events
- 23 Mar 2004 Nuada's FF2 programme is available for partnering (http://www.nuadapharma.com)
- 23 Mar 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
- 23 Mar 2004 Preclinical trials in Urinary incontinence in USA (unspecified route)